José García-Sánchez

A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial

Ross A. Soo, Ji‐Youn Han, Urania Dafni et al. · Annals of Oncology · 2021 · 116 citations · Full text

Medicine, Oncology, Pharmacotherapy +10

Predictive and prognostic clinical and pathological factors of nivolumab efficacy in non-small-cell lung cancer patients

J. Garde, Paloma Martín-Martorell, María De Julián et al. · Clinical & Translational Oncology · 2018 · 56 citations

Medicine, Oncology, Pharmacotherapy +12

A sustainable model for pediatric oncology nursing education in low‐income countries

Sara W. Day, José García-Sánchez, Federico Antillón et al. · Pediatric Blood & Cancer · 2011 · 50 citations

Nursing, Oncology Nursing, Pediatric Nursing +13

Intercalated Dosing Schedule of Erlotinib and Docetaxel as a Therapeutic Strategy to Avoid Antagonism and Optimize Its Benefits in Advanced Non–Small-Cell Lung Cancer. A Randomized Phase II Clinical Trial

Óscar Juan, Francisco Aparisi, Alfredo Sánchez-Hernández et al. · Clinical Lung Cancer · 2014 · 14 citations

Medicine, Oncology, Pharmacology +14

Management of Advanced Pancreatic Cancer with Gemcitabine Plus Erlotinib: Efficacy and Safety Results in Clinical Practice

Robert Díaz Beveridge, Vicent Alcolea, Jorge Aparicio et al. · PubMed · 2013 · 13 citations · Full text

Medicine, Oncology, Pharmacotherapy +17